The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
Fomento Economico Mexicano SAB de CV ADR
FMX · the NYSE · USD · Market cap $45.1B · 370,426 employees
Fomento Económico Mexicano, S.A.B.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 10:20 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price131.91 USD at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $95.40 to $121.59, base estimate $105.73 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Fomento Economico Mexicano SAB de CV ADR holds its Markup at $131.91. The statistical read favours the buyers, held for 586 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 586 days |
| Price at the screen | $131.91 |
| Valuation | 8.57 trailing · 25.74 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.09 |
Five Screens, Shown in Full
Does not pass. Excluded industry: Beverages - Brewers
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Excluded industry: Beverages - Brewers | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Fomento Economico Mexicano SAB de CV does not clear the screen at the business-activity stage. It operates in alcohol, so the financial ratios are not the deciding factor here.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when FMX's ethical verdict changes
Today FMX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $105.73 fair value estimate, narrow competitive moat, 9.80% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 24.8% above the base estimate.
Third-party analyst targets: 15 covering, consensus Buy. The average target sits +2% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere our models see it going: fair-value estimate $105.73, with a range of $95.40 to $121.59, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsEthics block this Mexican Coke bottler
Think of the truck that delivers Coke to corner shops in Guadalajara. FEMSA owns that route, yet the business lands straight on our excluded list because it sits in beverages. At 129 dollars against a fair value of 118, the shares already price in perfection while revenue grows just 6 percent and the forward multiple sits at 24 times.
We pass for the ethical breach first. The narrow moat, 3 percent profit margin and 12 percent return on equity do not change the fact that this remains an industry we have ruled out. Analyst chatter about a 131 dollar target does not move the needle once the screen has spoken.
The real risk is simple: any slip in Mexican volumes or peso moves would hit earnings quickly, and the current premium leaves little room for that outcome. Analysis, not advice.
| Forward P/E | 25.7xexpensive even after accounting for its growth |
| Trailing P/E | 8.6xvery cheap relative to earnings |
| EPS, trailing | 15.45 |
| EPS, forward | 5.15 |
| Revenue growth | +9.8%steady growth |
| Profit margin | 4.0%barely profitable |
| Return on equity | 15.0%a solid return on shareholder capital |
| FCF yield | 196.32% |
| Dividend yield | 5.31% |
| Debt to equity | 0.82moderate, manageable leverage |
| Current ratio | 1.15adequate liquidity, worth monitoring |
| Beta | 0.09barely tracks the market's swings |
| 52-week range | 92.55 - 141.47 |
| Moat | NARROW |
| Market cap | $45.1B |
| Employees | 370,426 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Mexico and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeFMX trades on the NYSE (the company is based in Mexico). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (15 analysts) rates it buy, with a mean price target of $125.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- FEMSA Q3 Earnings Miss Estimates Despite Strong OXXO Sales Yahoo Finance · 18d ago
- Fomento Economico Mexicano Q3 Earnings Call Highlights Yahoo Finance · 19d ago
- Fomento Economico: Q3 Earnings Snapshot Yahoo Finance · 19d ago
- FEMSA (FMX) Q2 2026 Earnings Call Transcript Yahoo Finance · 19d ago
- FEMSA Announces Third Quarter 2026 Results Yahoo Finance · 19d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $123.12 | +0.1% | · | $1,001 | +0.1% |
| 2 months | $114.80 | +7.4% | $1.80 | $1,089 | +8.9% |
| 3 months | $105.66 | +16.6% | $1.80 | $1,183 | +18.3% |
| 6 months | $101.00 | +22.0% | $1.80 | $1,238 | +23.8% |
| 1 year | $101.73 | +21.2% | $3.76 | $1,248 | +24.8% |
| 2 years | $100.55 | +22.6% | $8.47 | $1,310 | +31.0% |
| 3 years | $97.02 | +27.0% | $10.62 | $1,380 | +38.0% |
| 5 years | $75.15 | +64.0% | $13.90 | $1,825 | +82.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever FMX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.